Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

HSA Approval

TAFINLAR DISPERSIBLE TABLET 10MG

Approval Number

SIN17019P

Drug Name

TAFINLAR DISPERSIBLE TABLET 10MG

Product Name

TAFINLAR DISPERSIBLE TABLET 10MG

Approval Date

June 3, 2024

Registrant

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

Registrant

NOVARTIS (SINGAPORE) PTE LTD

Drug Type

Therapeutic

Forensic Classification

Prescription Only

Formulation Information

Dosage Form

TABLET, FOR SUSPENSION

Route of Administration

ORAL

Medical Information

ATC Code

L01EC02

Manufacturer Information

Pharmaceutical Manufacturer

NOVARTIS (SINGAPORE) PTE LTD

Manufacturers

Novartis Pharma Stein AG

Active Ingredients

Ingredient Name

Dabrafenib mesylate eqv Dabrafenib

Strength

10mg

Drug MonographDabrafenib

Documents

Package Inserts

Tafinlar PI.pdf

Approved: June 3, 2024

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

TAFINLAR DISPERSIBLE TABLET 10MG - HSA Approval | MedPath